All In MedTech

Device Trial Radar · NCT06528600

Comparative Study of Two Hyaluronic Acid Formulation in the Management of Knee Osteoarthritis

A Randomized, Double-Blind, Active Controlled, Multi-Center, Non- Inferiority Study of One-injection of Hymovis ONE (32 mg/4ml) Against Currently Approved 1-injection Regimen of Monovisc in Symptomatic Relief of Osteoarthritis of the Knee

Last checked: Nov 19, 2026Latest source record: Jul 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

350

Actual

Start

Sep 16, 2020

Primary completion

Mar 15, 2024

Study completion Jun 15, 2024

Sponsor

Lead sponsor
Fidia Farmaceutici s.p.a.Not on our public-company list
Sponsor type
Industry
First posted
Jul 30, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this randomized, double-blind, active-controlled, non-inferiority study is to compare the effectiveness and safety of a single injection of Hymovis ONE®, a sodium hyaluronate formulation, to Monovisc™, another sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens. This study consists of a 2-week period for screening, one baseline treatment visit, and a 26- week evaluation phase. Subjects will be randomized to receive a single intra-articular (IA) injection of either Hymovis ONE® or Monovisc™ into the knee using an 18-20 gauge needle.

Conditions

  • Osteoarthritis, Knee

Interventions

  • Hymovis ONEDevice

    Single injection of Hymovis ONE®, a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens

  • MonoviscDevice

    Single injection of Monovisc™ a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain relief compared to baselineTime frame: week 12

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • A.O. Ospedale Cardarelli I Ortopedia

    Naples, Italy

  • AOU Federico II Napoli UOC Ortopedia e Traumatologia

    Naples, Italy

  • P.O. Ospedale del Mare ASL 1 Napoli U.O.C. Ortopedia

    Naples, Italy

16 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.